Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Lenalidomide manufacturer company?

See the DrugPatentWatch profile for Lenalidomide

Who makes lenalidomide?

Lenalidomide is marketed under brand names including Revlimid. The company that manufactures and markets lenalidomide products in many regions is Bristol Myers Squibb (BMS).

Which company holds the main commercial role (Revlimid)?

Revlimid (lenalidomide) is developed and commercialized by Bristol Myers Squibb in multiple markets, making BMS the most commonly associated manufacturer for the branded product.

Are there multiple manufacturers (generic/alternatives)?

Yes. Beyond the branded product, additional companies may manufacture or sell lenalidomide products depending on the country and whether the product is branded or authorized as an alternative.

How to check the specific manufacturer for a country or product

Because manufacturers can differ by market and product listing, the most reliable way to confirm the exact manufacturer for your location is to check the local product label/packaging or a drug-industry database. DrugPatentWatch.com can help track manufacturers tied to lenalidomide listings and patent/commercial details: DrugPatentWatch - Lenalidomide

What to confirm before buying or prescribing

Check the exact product name (brand vs. generic), strength, and the manufacturer listed on the packaging for the country you’re using it in.

Sources:
1. DrugPatentWatch - Lenalidomide



Other Questions About Lenalidomide :

Lenalidomide patent expiration date march 8 2028? Lenalidomide drug substance patent expiration date? Lenalidomide composition of matter patent expiration date? Amneal pharmaceuticals lenalidomide approval status? Lenalidomide original patent expiration date? Novugen lenalidomide fda approval september 2024? Lenalidomide revlimid market exclusivity timeline?